| Umer Hafeez Siddiqui, MD | |
|
901 Patients First Dr, Washington, MO 63090-4700 | |
| (636) 231-6245 | |
| (636) 231-6244 |
| Full Name | Umer Hafeez Siddiqui |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 21 Years |
| Location | 901 Patients First Dr, Washington, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245251321 | NPI | - | NPPES |
| 036116212 | Medicaid | IL | |
| 1245251321 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 2007038366 (Missouri) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 036.116212 (Illinois) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Washington | Washington, MO | Hospital |
| Mercy Hospital St Louis | Saint louis, MO | Hospital |
| Mercy Hospital Lebanon | Lebanon, MO | Hospital |
| Mercy Hospital Lincoln | Troy, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinic Pulmonology Washington Llc | 4981728615 | 3 |
News Archive
Doctors already know that obesity is a risk factor for developing heart disease. However, how obesity affects people with established heart disease has been unclear because previous studies have had contradictory results.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
Writing in the ONE Blog, Neeraj Mistry, managing director of the Global Network for Neglected Tropical Diseases, highlights two reports released last week that examine global efforts against neglected tropical diseases (NTDs) one year after the London Declaration, as well as a report by the Hudson Institute, also released last week, which "highlight[s] the crucial links between NTDs and broader economic and societal consequences."
The Focused Ultrasound Surgery Foundation today issued a reminder that early bird registration discounts will end on Saturday, July 31 for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound.
› Verified 6 days ago
| Entity Name | Mercy Clinic Adult Hospitalists - Washington, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891943429 PECOS PAC ID: 3577630540 Enrollment ID: O20080917000782 |
News Archive
Doctors already know that obesity is a risk factor for developing heart disease. However, how obesity affects people with established heart disease has been unclear because previous studies have had contradictory results.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
Writing in the ONE Blog, Neeraj Mistry, managing director of the Global Network for Neglected Tropical Diseases, highlights two reports released last week that examine global efforts against neglected tropical diseases (NTDs) one year after the London Declaration, as well as a report by the Hudson Institute, also released last week, which "highlight[s] the crucial links between NTDs and broader economic and societal consequences."
The Focused Ultrasound Surgery Foundation today issued a reminder that early bird registration discounts will end on Saturday, July 31 for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound.
› Verified 6 days ago
| Entity Name | Mercy Clinic Pulmonology Washington Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699086926 PECOS PAC ID: 4981728615 Enrollment ID: O20100901000242 |
News Archive
Doctors already know that obesity is a risk factor for developing heart disease. However, how obesity affects people with established heart disease has been unclear because previous studies have had contradictory results.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
Writing in the ONE Blog, Neeraj Mistry, managing director of the Global Network for Neglected Tropical Diseases, highlights two reports released last week that examine global efforts against neglected tropical diseases (NTDs) one year after the London Declaration, as well as a report by the Hudson Institute, also released last week, which "highlight[s] the crucial links between NTDs and broader economic and societal consequences."
The Focused Ultrasound Surgery Foundation today issued a reminder that early bird registration discounts will end on Saturday, July 31 for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound.
› Verified 6 days ago
| Entity Name | St Anthonys Physician Organization Hospitalist Services Lc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407216336 PECOS PAC ID: 5092980656 Enrollment ID: O20111208000771 |
News Archive
Doctors already know that obesity is a risk factor for developing heart disease. However, how obesity affects people with established heart disease has been unclear because previous studies have had contradictory results.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
Writing in the ONE Blog, Neeraj Mistry, managing director of the Global Network for Neglected Tropical Diseases, highlights two reports released last week that examine global efforts against neglected tropical diseases (NTDs) one year after the London Declaration, as well as a report by the Hudson Institute, also released last week, which "highlight[s] the crucial links between NTDs and broader economic and societal consequences."
The Focused Ultrasound Surgery Foundation today issued a reminder that early bird registration discounts will end on Saturday, July 31 for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound.
› Verified 6 days ago
| Entity Name | Mercy Clinic Adult Hospitalists Jefferson Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083052492 PECOS PAC ID: 8628205598 Enrollment ID: O20131220001798 |
News Archive
Doctors already know that obesity is a risk factor for developing heart disease. However, how obesity affects people with established heart disease has been unclear because previous studies have had contradictory results.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
Writing in the ONE Blog, Neeraj Mistry, managing director of the Global Network for Neglected Tropical Diseases, highlights two reports released last week that examine global efforts against neglected tropical diseases (NTDs) one year after the London Declaration, as well as a report by the Hudson Institute, also released last week, which "highlight[s] the crucial links between NTDs and broader economic and societal consequences."
The Focused Ultrasound Surgery Foundation today issued a reminder that early bird registration discounts will end on Saturday, July 31 for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound.
› Verified 6 days ago
| Entity Name | Mercy Hospital Lincoln |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962808733 PECOS PAC ID: 5193040020 Enrollment ID: O20150623002541 |
News Archive
Doctors already know that obesity is a risk factor for developing heart disease. However, how obesity affects people with established heart disease has been unclear because previous studies have had contradictory results.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
Writing in the ONE Blog, Neeraj Mistry, managing director of the Global Network for Neglected Tropical Diseases, highlights two reports released last week that examine global efforts against neglected tropical diseases (NTDs) one year after the London Declaration, as well as a report by the Hudson Institute, also released last week, which "highlight[s] the crucial links between NTDs and broader economic and societal consequences."
The Focused Ultrasound Surgery Foundation today issued a reminder that early bird registration discounts will end on Saturday, July 31 for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Umer Hafeez Siddiqui, MD 901 Patients First Dr, Washington, MO 63090-4700 Ph: (636) 231-6245 | Umer Hafeez Siddiqui, MD 901 Patients First Dr, Washington, MO 63090-4700 Ph: (636) 231-6245 |
News Archive
Doctors already know that obesity is a risk factor for developing heart disease. However, how obesity affects people with established heart disease has been unclear because previous studies have had contradictory results.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
Writing in the ONE Blog, Neeraj Mistry, managing director of the Global Network for Neglected Tropical Diseases, highlights two reports released last week that examine global efforts against neglected tropical diseases (NTDs) one year after the London Declaration, as well as a report by the Hudson Institute, also released last week, which "highlight[s] the crucial links between NTDs and broader economic and societal consequences."
The Focused Ultrasound Surgery Foundation today issued a reminder that early bird registration discounts will end on Saturday, July 31 for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound.
› Verified 6 days ago
Dr. Isaac I Cohen, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 901 Patients First Drive, Washington, MO 63090 Phone: 636-390-1600 Fax: 636-390-1601 | |
Sudhanshu Gogia, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr, Washington, MO 63090 Phone: 636-239-7344 Fax: 636-239-9436 | |
Dr. Nicholas W Frederickson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Drive Suite 3300, Washington, MO 63090 Phone: 636-239-7344 Fax: 636-239-9436 | |
Dr. John R Douglas Peterson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr Ste 3300, Washington, MO 63090 Phone: 636-239-7344 | |
Mohan Mallikarjuna Edupuganti, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr Ste 2500, Washington, MO 63090 Phone: 636-239-2711 | |
Dr. Roberto Pacheco-coronado, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr Ste 2500, Washington, MO 63090 Phone: 636-239-2711 | |
Lydia Luisa Archuleta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 901 E 5th St, Washington, MO 63090 Phone: 636-239-8000 |